Nodigap (Colecalciferol)

Colecalciferol is converted in the liver and kidneys to the active hormone 1,25‑dihydroxyvitamin D. This hormone binds to vitamin D receptors, increasing the expression of calcium‑binding proteins in the intestine, which enhances calcium and phosphate absorption and promotes bone mineralization.

The appropriate dose of Nodigap is determined by a prescriber based on the individual’s serum vitamin D level, age, weight, and clinical condition. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for colecalciferol in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the use of Nodigap with their healthcare provider to weigh potential benefits and risks.

To order Nodigap, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nodigap contains colecalciferol, the same form of vitamin D found in most over‑the‑counter supplements. Compared with ergocalciferol (vitamin D2), colecalciferol generally provides more consistent and longer‑lasting increases in serum vitamin D levels, making it a preferred choice for many clinicians.

Store Nodigap at ambient temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children.

Nodigap is taken orally, usually with or without food, as directed by a healthcare professional. The tablet or capsule should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

The most serious risk is severe hypercalcemia, which can cause confusion, cardiac arrhythmias, kidney stones, and renal impairment. Patients experiencing symptoms such as persistent nausea, vomiting, excessive thirst, or muscle weakness should seek medical attention promptly.

Individuals with known hypersensitivity to colecalciferol or any excipients in the product should avoid Nodigap. It is also contraindicated in patients with severe hypercalcemia or certain rare metabolic disorders unless supervised by a specialist.